Videos

LATEST VIDEOS

New Frontiers in Hematology: From CLL Tumor Precursor Cells to Tracking Disease Burden in Multiple Myeloma

FEATURED PRESENTERS
Marc Seifert, PD Dr. rer. Nat.

June 14th, 2021|

Watch video

Complementary Value of MRD Assessments by NGS and MFC for the Study of Hematologic Malignancies

FEATURED PRESENTERS
Ola Landgren, PhD, MD / Swati Shah, MD

December 1st, 2020|

Watch video

Artificial Intelligence (AI) and other Data Science Applications in Molecular Pathology

FEATURED PRESENTER
Dr. Bradley Patay

November 16th, 2020|

Watch video

Clinical Utility of NGS in Lymphoid Malignancies including Minimal Residual Disease (MRD) testing

FEATURED PRESENTERS
Yury Monczak, Ph.D / Ryan J. Schmidt, MD, PhD

November 16th, 2020|

Watch video

VIRTUAL EHA: Next Generation Analysis in CLL and Other Malignancies

FEATURED PRESENTERS
Prof. Dr. Markus Tiemann

June 14th, 2020|

Watch video

Previous 567 Next

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

Videos

Videos

LATEST VIDEOS

Global Search

SEARCH BY KEYWORD

Global Search

SEARCH BY KEYWORD

Looking for Product Documents?
Try our New Document Search Feature ⟶

Looking for Product Documents?
Try our New Document Search Feature ⟶

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

Videos

Videos

LATEST VIDEOS

New Frontiers in Hematology: From CLL Tumor Precursor Cells to Tracking Disease Burden in Multiple Myeloma

Complementary Value of MRD Assessments by NGS and MFC for the Study of Hematologic Malignancies

Artificial Intelligence (AI) and other Data Science Applications in Molecular Pathology

Clinical Utility of NGS in Lymphoid Malignancies including Minimal Residual Disease (MRD) testing

VIRTUAL EHA: Next Generation Analysis in CLL and Other Malignancies

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.